In vitro and in vivo evaluation of a18F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Varasteh, Zohreh ^a   Åberg, Ola ^a   Velikyan, Irina ^a,b   Lindeberg, Gunnar ^a   Sörensen, Jens ^a,b   Larhed, Mats ^a   Antoni, Gunnar ^a,b   Sandström, Mattias ^b   Tolmachev, Vladimir ^a   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; BOMBESIN ANTAGONIST; FLUORINE 18; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER CELL; CHELATION; CONJUGATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; MOUSE; NEOPLASM; NONHUMAN; PANCREAS; PC 3 CELL; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOACTIVITY; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BOMBESIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG STABILITY; ETHYLENE GLYCOLS; FLUORINE RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HUMANS; LIGANDS; MALE; MICE; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RECEPTORS, BOMBESIN;

EID: 84891695913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081932     Document Type: Article

References (33)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer Statistics, The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths. CA: a Cancer Journal for Clinicians 61: 212-236. doi:10.3322/caac.20121.
2. Kelloff GJ, Choyke P, Coffey DS et al. (2009) Challenges in Clinical Prostate Cancer: Role of Imaging. AJR Am J Roentgenol 192: 1455-1470. doi:10.2214/AJR.09.2579. PubMed: 19457806.
3. Even-Sapir E (2005) Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities. J Nucl Med 46: 1356-1367. PubMed: 16085595.
4. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ (2009) Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69: 1101-1108. doi:10.1002/pros.20957. PubMed: 19343734.
5. Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59: 1152-1159. PubMed: 10070977.
6. de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M et al. (2007) Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J Nucl Med 48: 88-93. PubMed: 17204703.
7. Jian Xiaoying, Sainz Eduardo, Clark William A, Jensen Robert T, Battey et al James F. (1999) The bombesin receptor subtypes have distinct G protein specificities. J Biol Chem 274: 11573-11581. doi:10.1074/jbc.274.17.11573. PubMed: 10206964.
8. Bodei LFM, Nunn J, Llull J, Cremonesi M, Martano L et al. (2007) 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. European Association of Nuclear; Medicine (2007) abstract 463
9. Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F et al. (2011) Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 52: 1970-1978. doi:10.2967/jnumed.111.094375. PubMed: 22080443.
10. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D et al. (2008) Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting. J Nucl Med 49: 318-326. doi:10.2967/jnumed.107.045054. PubMed: 18199616.
11. Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML et al. (2009) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15: 5240-5249. doi:10.1158/1078-0432.CCR-08-3145. PubMed: 19671861.
12. Varasteh Z, Velikyan I, Lindeberg G, Sörensen J, Larhed M et al. (2013) Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. Bioconjug Chem, 24: 1144-53. doi:10.1021/bc300659k. PubMed: 23763444.
13. Mansi R, Wang X, Forrer F, Waser B, Cescato R et al. (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38: 97-107. doi:10.1007/s00259-010-1596-9. PubMed: 20717822.
14. Cho ZH, Chan JK, Ericksson L, Singh M, Graham S et al. (1975) Positron ranges obtained from biomedically important positron-emitting radionuclides. J Nucl Med 16: 1174-1176. PubMed: 1194970.
15. Tolmachev V, Stone-Elander S (2010) Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. Biochim Biophys Acta. 1800: 487-510. doi:10.1016/j.bbagen.2010.02.002. PubMed: 20153401.
16. Schirrmacher R, Bradtmöller G, Schirrmacher E, Thews O, Tillmanns J et al. (2006) 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed Engl 45: 6047-6050. doi:10.1002/anie. 200600795. PubMed: 16888726.
17. Wängler C, Niedermoser S, Chin J, Orchowski K, Schirrmacher E et al. (2012) One-step (18)F-labeling of peptides for positron emission tomography imaging using the SiFA methodology. Nat Protoc 7: 1946-1955. doi:10.1038/nprot.2012.109. PubMed: 23037309.
18. McBride WJ, Sharkey RM, Karacay H, D'Souza CA, Rossi EA et al. (2009) A Novel Method of 18F Radiolabeling for PET. J Nucl Med 50: 991-998. doi:10.2967/jnumed.108.060418. PubMed: 19443594.
19. Schwarzenböck S, Souvatzoglou M, Krause BJ (2012) Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer. Theranostics 2: 318-330. doi:10.7150/thno.4008. PubMed: 22448198.
20. Pinto F, Totaro A, Palermo G, Calarco A, Sacco E et al. (2012) Imaging in prostate cancer staging: present role and future perspectives. Urol Int 88: 125-136. doi:10.1159/000335205. PubMed: 22286304.
21. Jadvar H (2013) Imaging evaluation of prostate cancer with (18)Ffluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging 40: 5-10. doi:10.1007/s00259-013-2361-7.
22. Dimitrakopoulou-Strauss A, Strauss LG (2003) PET Imaging of Prostate Cancer with 11 C-Acetate. J Nucl Med 44: 556-558. PubMed: 12679399.
23. Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara H et al. (2012) Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med 26: 138-145. doi:10.1007/s12149-011-0551-6. PubMed: 22069194.
24. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA et al. (2005) Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32: 344-350. doi:10.1007/s00259-005-1764-5. PubMed: 15726353.
25. Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A et al. (2011) Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med 52: 1608-1615. doi:10.2967/jnumed.111.092098. PubMed: 21908391.
26. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM et al. (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51: 1293-1300. doi:10.2967/jnumed.110.076174. PubMed: 20660376.
27. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate. Cancer. J - Nucl Med. doi:10.2967/jnumed.112.116624.
28. Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA et al. (2013) First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 54: 380-387. doi:10.2967/jnumed.112.111203. PubMed: 23303962.
29. Eder M, Eisenhut M, Babich J, Haberkorn U (2013) PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 40: 819-823. doi:10.1007/s00259-013-2374-2. PubMed: 23463331.
30. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ (2009) Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69: 1101-1108. doi:10.1002/pros.20957. PubMed: 19343734.
31. Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF et al. (2012) Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. Prostate 72: 318-325. doi:10.1002/pros.21434. PubMed: 21739464.
32. Ginj M, Zhang H, Waser B, Cescato R, Wild D et al. (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 103: 16436-16441. doi:10.1073/pnas.0607761103. PubMed: 17056720.
33. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D et al. (2003) [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30: 247-258. doi:10.1007/s00259-002- 1040-x. PubMed: 12552343.